Veradermics, Incorporated financials
$117.82+2.45%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$29.6M | -$29.9M |
| Net income | -$23.5M | -$30.0M |
| Net margin | — | — |
| Diluted EPS | $-0.58 | $-1.32 |
| EBITDA | -$29.6M | -$29.9M |
| Operating cash flow | -$14.5M | -$21.2M |
| Free cash flow | -$14.5M | -$21.2M |
| Diluted shares | 40.4M | 22.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 |
|---|---|---|
| Cash & equivalents | $319.3M | $168.4M |
| Short-term investments | $500.6M | $222.4M |
| Total debt | $0.00 | $0.00 |
| Total assets | $825.7M | $397.4M |
| Total liabilities | $12.1M | $6.7M |
| Shareholders' equity | $813.6M | $390.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology